KURA ONCOLOGY, INC. Available-for-sale Securities, Gross Realized Gain (Loss)
KURA ONCOLOGY, INC. (KURA) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $0 for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2018-11-05
- KURA ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-09-30 was $0.00.
- KURA ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-06-30 was $0.00.
- KURA ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-03-31 was $0.00.
- KURA ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-12-31 was $0.00.
- KURA ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $0.00.
- KURA ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $0.00.
- KURA ONCOLOGY, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2015 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2018-09-30 | $0.00 10-Q · filed 2018-11-05 | $0.00 derived: sum of 2 quarters · filed 2018-11-05 | $0.00 10-Q · filed 2018-11-05 | $0.00 derived: sum of 4 quarters · filed 2018-11-05 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-06 | $0.00 10-Q · filed 2018-08-06 | $0.00 derived: sum of 3 quarters · filed 2018-08-06 | $0.00 derived: sum of 4 quarters · filed 2018-08-06 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | $0.00 derived: sum of 2 quarters · filed 2018-05-08 | $0.00 derived: sum of 3 quarters · filed 2018-05-08 | $0.00 derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $0.00 derived: sum of 3 quarters · filed 2018-03-12 | $0.00 10-K · filed 2018-03-12 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | $0.00 derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $0.00 10-Q · filed 2017-08-07 | $0.00 derived: sum of 3 quarters · filed 2018-03-12 | $0.00 derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $0.00 derived: sum of 3 quarters · filed 2018-03-12 | $0.00 derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $0.00 derived: sum of 3 quarters · filed 2018-03-12 | $0.00 10-K · filed 2018-03-12 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-07 | $0.00 derived: sum of 2 quarters · filed 2016-11-07 | $0.00 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-10 | $0.00 10-Q · filed 2016-08-10 | ||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-11 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |